Roche collaborator MediLink released interim Phase 3 results for tambotatug pelitecan (Tam-Peli; YL201) in Chinese patients with relapsed small-cell lung cancer. In the TAISHAN-302 trial, Tam-Peli versus topotecan met the primary endpoint of overall survival, cutting the risk of death by 54% (median OS 13.3 vs. 9.4 months; HR=0.46; p<0.0001). The trial also reported progression-free survival benefits (median PFS 7.4 vs. 2.8 months) and a higher objective response rate (59.1% vs. 9.7%). The company said overall findings are being presented as a late-breaking abstract at IASLC 2026 and will be published in The New England Journal of Medicine. Separately, China’s NMPA CDE accepted the NDA for filing, and Roche plans to develop and commercialize Tam-Peli outside mainland China, Hong Kong, and Macau across multiple tumor types with global trials planned.